Drug
Ribavarin
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph not_applicable
1
50%
Ph phase_3
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Terminated(1)
Other(1)
Detailed Status
unknown1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
unknown150%
withdrawn150%
Recent Activity
0 active trials
Showing 2 of 2
withdrawnphase_3
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
NCT02204475
unknownnot_applicable
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
NCT00842205
Clinical Trials (2)
Showing 2 of 2 trials
NCT02204475Phase 3
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
NCT00842205Not Applicable
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2